BioStem Technologies (BSEM)
OTHER OTC:BSEM
Want to see BSEM full AI Analyst Report?
BSEM Stock Chart & Stats
$4.83
$0.88(5.85%)
At close: 4:00 PM EST
$4.83
$0.88(5.85%)
Day’s Range― - ―
52-Week Range$3.09 - $14.52
Previous CloseN/A
Volume47.30K
Average Volume (3M)65.14K
Market Cap
$67.56M
Enterprise Value$59.15M
Total Cash (Recent Filing)$29.55M
Total Debt (Recent Filing)$3.33M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 25, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding16,338,436
10 Day Avg. Volume93,371
30 Day Avg. Volume65,136
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.25
Enterprise Value/Gross Profit1.34
Enterprise Value/Ebitda-125.92
Forecast
1Y Price Target
$7.00Price Target Upside44.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$45.84M
Bulls Say, Bears Say
Bulls Say
Acquisition Expands Hospital ChannelsThe BioTissue acquisition materially broadens BioStem's addressable market into hospitals, HOPDs and ASCs and diversifies payer mix. This structural change creates more stable, higher-volume hospital channels and reduces dependence on physician-office reimbursement dynamics over the medium term.
Randomized Clinical Superiority (DFU)A randomized controlled trial showing DFU superiority is a durable competitive advantage: clinical differentiation supports stronger hospital adoption, payer coverage negotiations, and standard-of-care positioning, underpinning sustainable volume growth and pricing power over multiple quarters.
Manufacturing Margin Upside Via Tech TransferPlanned tech transfer and in‑house manufacturing represent a structural gross-margin lever: moving from ~60% outsourced margins to >80% could sustainably boost gross profit and free cash flow, improving long-term unit economics and reducing reliance on contract manufacturers.
Bears Say
Sharp, Volatile Revenue And EarningsThe company exhibits pronounced revenue and earnings volatility, with a multi-quarter collapse and return to losses. Such structural instability undermines visibility, stresses operating leverage, and raises execution risk for commercial expansion and margin recovery over the next several quarters.
Post-acquisition Cash Reduction And Limited RunwayMaterial cash depletion post-close and a runway into late Q3 2026 create structural financing risk. Ongoing integration costs, contingent payments, and operating losses mean management must execute near-term funding or operational improvements to avoid dilution or constrained investment in commercialization.
Collections, Reimbursement And Allowance RiskA large allowance tied to distributor receivables and CMS payment changes signals structural cash-collection and reimbursement exposure. Persistent payer audit risk and revenue clawbacks could compress working capital and force conservative commercial growth, limiting predictable cash conversion over many quarters.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $3.09 and its highest was $14.52 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $67.56M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s upcoming earnings report date is Aug 25, 2026 which is in 91 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on May 14, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.24.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Undervalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate is -0.5.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 16,338,436 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -14.167%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (44.93% Upside)
$7.00 (44.93% Upside)
Blogger Sentiment
Bullish
BSEM Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.53%
12-Months-Change
Fundamentals
Return on Equity
-47.03%
Trailing 12-Months
Asset Growth
-63.11%
Trailing 12-Months
Company Description
BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
BSEM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call communicated meaningful strategic positives — a transformational acquisition expanding addressable markets, strong clinical data (DFU RCT), product and commercial expansion, and a clear path to materially higher manufacturing margins after tech transfer. However, these longer-term strengths are offset by significant near-term financial headwinds: steep year-over-year revenue declines, a sizable one-time $8.8M allowance tied to distributor collections, higher operating expenses, lower blended margins during a 12-month contract manufacturing period, reduced post-close cash (~$16M) and expected cash consumption through much of 2026. Management has articulated a credible integration and commercialization plan, but near-term liquidity and execution risks temper the outlook.View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
$7.00
▲(44.93% Upside)
Technical Analysis
Crescent Biopharma
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Innate Pharma
―